Does recall period matter? Comparing PROMIS


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Mar 2020
Historique:
accepted: 21 10 2019
pubmed: 9 11 2019
medline: 5 6 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

To evaluate the influence of recall periods on the assessment of physical function, we compared, in cancer and general population samples, the standard administration of PROMIS Physical Function items without a recall period to administrations with 24-hour and 7-day recall periods. We administered 31 items from the PROMIS Physical Function v2.0 item bank to 2400 respondents (n = 1001 with cancer; n = 1399 from the general population). Respondents were randomly assigned to one of three recall conditions (no recall, 24-hours, or 7-days) and one of two "reminder" conditions (with recall periods presented only at the start of the survey or with every item). We assessed items for potential differential item functioning (DIF) by recall time period. We then tested recall and reminder effects with analysis of variance controlling for demographics, English fluency, and co-morbidities. Based on conservative pre-set criteria, no items were flagged for recall time period-related DIF. Using analysis of variance, each condition was compared to the standard PROMIS administration for Physical Function (no recall period). There was no evidence of significant differences among groups in the cancer sample. In the general population sample, only the 24-hour recall condition with reminders was significantly different from the "no recall" PROMIS standard. At the item level, for both samples, the number of items with non-trivial effect size differences across conditions was minimal. Compared to no recall, the use of a recall period has little to no effect upon PROMIS physical function responses or scores. We recommend that PROMIS Physical Function be administered with the standard PROMIS "no recall" period.

Identifiants

pubmed: 31701432
doi: 10.1007/s11136-019-02344-0
pii: 10.1007/s11136-019-02344-0
pmc: PMC7199782
mid: NIHMS1564666
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

745-753

Subventions

Organisme : NIA NIH HHS
ID : R01 AG018436
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA186878
Pays : United States
Organisme : NIH HHS
ID : U2CCA186878
Pays : United States

Références

JAMA. 2018 Feb 6;319(5):483-494
pubmed: 29411037
Qual Life Res. 2009 Sep;18(7):873-80
pubmed: 19543809
J Clin Epidemiol. 2010 Nov;63(11):1169-78
pubmed: 20688473
J Clin Epidemiol. 2014 May;67(5):516-26
pubmed: 24698295
Assessment. 2019 Mar;26(2):249-259
pubmed: 28052687
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
Med Care. 2007 May;45(5 Suppl 1):S12-21
pubmed: 17443114
J Anxiety Disord. 2014 Jan;28(1):88-96
pubmed: 24508596
Science. 1987 Apr 10;236(4798):157-61
pubmed: 3563494
Ann Oncol. 2013 Apr;24(4):1073-8
pubmed: 23136235
Qual Life Res. 2014 Nov;23(9):2439-45
pubmed: 24848596
J Clin Epidemiol. 2008 Jan;61(1):17-33
pubmed: 18083459
Qual Life Res. 2009 May;18(4):447-60
pubmed: 19294529
J Clin Epidemiol. 2009 Sep;62(9):991-7
pubmed: 19216054
J Clin Epidemiol. 2016 May;73:89-102
pubmed: 26952842
Arthritis Care Res (Hoboken). 2013 Oct;65(10):1625-33
pubmed: 23592494
Psychol Bull. 1990 Mar;107(2):238-46
pubmed: 2320703
Qual Life Res. 2018 Jul;27(7):1885-1891
pubmed: 29569016
Qual Life Res. 2010 Oct;19(8):1163-70
pubmed: 20535565
Pain. 1996 Jul;66(1):3-8
pubmed: 8857625
Psychol Methods. 2016 Jun;21(2):137-50
pubmed: 26523435
Pain. 1990 Jun;41(3):255-65
pubmed: 1697054
J Pers Assess. 2013;95(2):129-40
pubmed: 23030794
J Pers Assess. 2010 Nov;92(6):544-59
pubmed: 20954056
J Gen Intern Med. 2015 Oct;30(10):1517-23
pubmed: 25990189
Psychol Bull. 2002 Nov;128(6):934-60
pubmed: 12405138
J Clin Epidemiol. 2016 May;73:128-34
pubmed: 26939927
J Clin Epidemiol. 2010 Nov;63(11):1195-204
pubmed: 20688471
J Clin Epidemiol. 2011 May;64(5):507-16
pubmed: 21447427
Qual Life Res. 2013 Aug;22(6):1161-75
pubmed: 22987144
Qual Life Res. 2015 Oct;24(10):2333-44
pubmed: 25935353
Qual Life Res. 2012 Aug;21(6):1013-20
pubmed: 21909804
Med Care. 2007 May;45(5 Suppl 1):S3-S11
pubmed: 17443116
J Stat Softw. 2011 Mar 1;39(8):1-30
pubmed: 21572908
Qual Life Res. 2007;16 Suppl 1:19-31
pubmed: 17479357
Arch Phys Med Rehabil. 2011 Oct;92(10 Suppl):S20-7
pubmed: 21958919
Curr Med Res Opin. 2009 Apr;25(4):929-42
pubmed: 19257798
Med Care. 2007 May;45(5 Suppl 1):S22-31
pubmed: 17443115
J Clin Oncol. 2007 Nov 10;25(32):5106-12
pubmed: 17991929
Pain. 2008 Sep 30;139(1):146-57
pubmed: 18455312
Qual Life Res. 2010 Nov;19(9):1311-21
pubmed: 20593306

Auteurs

David M Condon (DM)

Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Robert Chapman (R)

Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Sara Shaunfield (S)

Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Michael A Kallen (MA)

Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Jennifer L Beaumont (JL)

Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Terasaki Research Institute, Los Angeles, CA, USA.

Daniel Eek (D)

AstraZeneca, Gothenburg, Sweden.

Debanjali Mitra (D)

Pfizer, Inc., New York, NY, USA.

Katy L Benjamin (KL)

Health Economics and Outcomes Research, AbbvVie Inc., North Chicago, IL, USA.

Kelly McQuarrie (K)

Janssen Global Services, Malvern, PA, USA.

Jamae Liu (J)

Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

James W Shaw (JW)

Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Allison Martin Nguyen (A)

Merck & Co., Inc., Kenilworth, NJ, USA.

Karen Keating (K)

Bayer HealthCare Pharmaceuticals, Inc., West Haven, CT, USA.

David Cella (D)

Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. d-cella@northwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH